Alpha emitter radium-223 and survival in metastatic prostate cancer.
Authors
Parker, CNilsson, S
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Seke, M
Widmark, A
Johannessen, D
Hoskin, P
Bottomley, D
James, N
Solberg, A
Syndikus, I
Kliment, J
Wedel, S
Boehmer, S
Dall'Oglio, M
Franzén, L
Coleman, R
Vogelzang, N
O'Bryan-Tear, C
Staudacher, K
Garcia-Vargas, J
Shan, M
Bruland, Ø
Sartor, O
Affiliation
Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom.Issue Date
2013-07-18
Metadata
Show full item recordAbstract
Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.Citation
Alpha emitter radium-223 and survival in metastatic prostate cancer. 2013, 369 (3):213-23 N Engl J MedJournal
New England Journal of MedicineDOI
10.1056/NEJMoa1213755PubMed ID
23863050Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1213755